

**Specimen ID:** 245-988-9013-0  
**Control ID:****Acct #:** 90000999      **Phone:** (336) 436-8645      **Rte:** 00  
LabCorp Test Master  
Test Account  
5450 Millstream Road  
MCLEANSVILLE NC 27301**SAMPLE REPORT, 139900****Patient Details****DOB:** 03/15/1965  
**Age(y/m/d):** 055/05/17  
**Gender:** M  
**Patient ID:****Specimen Details****Date collected:** 09/01/2020 0000 Local  
**Date received:** 09/01/2020  
**Date entered:** 09/01/2020  
**Date reported:** 09/01/2020 0922 ET**Physician Details****Ordering:**  
**Referring:**  
**ID:**  
**NPI:****General Comments & Additional Information****Clinical Info:** NOT DETECTED**Ordered Items**

SARS-CoV-2, NAA

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

SARS-CoV-2, NAA	Not Detected			Not Detected	01
-----------------	--------------	--	--	--------------	----

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
----	----	--	--------------------------

For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 336-436-2762**

**Specimen ID:** 245-988-9014-0  
**Control ID:**
**Acct #:** 90000999      **Phone:** (336) 436-8645      **Rte:** 00  
 LabCorp Test Master  
 Test Account  
 5450 Millstream Road  
 MCLEANSVILLE NC 27301

**SAMPLE REPORT, 139900**

Patient Details	Specimen Details	Physician Details
<b>DOB:</b> 02/02/1982 <b>Age(y/m/d):</b> 038/06/30 <b>Gender:</b> M <b>Patient ID:</b>	<b>Date collected:</b> 09/01/2020 0000 Local <b>Date received:</b> 09/01/2020 <b>Date entered:</b> 09/01/2020 <b>Date reported:</b> 09/01/2020 0922 ET	<b>Ordering:</b> <b>Referring:</b> <b>ID:</b> <b>NPI:</b>

**General Comments & Additional Information**
**Clinical Info:** INDETERMINATE

**Ordered Items**

SARS-CoV-2, NAA

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

SARS-CoV-2, NAA	Indeterminate	Abnormal		Not Detected	01
-----------------	---------------	----------	--	--------------	----

We are **UNABLE** to reliably determine a result for the specimen due to the inconsistent amplification of all of the required SARS-CoV-2 components from the specimen submitted. If clinically indicated, please recollect an additional specimen for testing.

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
----	----	--	--------------------------

 For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 336-436-2762**

**Specimen ID:** 245-988-9015-0  
**Control ID:**
**Acct #:** 90000999      **Phone:** (336) 436-8645      **Rte:** 00  
 LabCorp Test Master  
 Test Account  
 5450 Millstream Road  
 MCLEANSVILLE NC 27301

**SAMPLE REPORT, 139900**

**Patient Details**
**DOB:** 07/04/1976  
**Age(y/m/d):** 044/01/28  
**Gender:** M  
**Patient ID:**
**Specimen Details**
**Date collected:** 09/01/2020 0000 Local  
**Date received:** 09/01/2020  
**Date entered:** 09/01/2020  
**Date reported:** 09/01/2020 0922 ET

**Physician Details**
**Ordering:**  
**Referring:**  
**ID:**  
**NPI:**
**General Comments & Additional Information**
**Clinical Info:** DETECTED

**Ordered Items**

SARS-CoV-2, NAA

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

SARS-CoV-2, NAA	Detected Abnormal			Not Detected	01
-----------------	-------------------	--	--	--------------	----

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
----	----	--	--------------------------

 For inquiries, the physician may contact **Branch: 800-222-7566 Lab: 336-436-2762**